Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature.
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
23
09
2019
revised:
29
01
2020
accepted:
01
02
2020
pubmed:
6
2
2020
medline:
15
5
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death-1 (PD-1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD-1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019.
Substances chimiques
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13250Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Al-Rohil, R. N., Tarasen, A. J., Carlson, J. A., Wang, K., Johnson, A., Yelensky, R., … Ross, J. S. (2016). Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer, 122(2), 249-257.
Assam, J. H., Powell, S., & Spanos, W. C. (2016). Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to programmed cell death protein 1 inhibitor therapy. Clin Skin Cancer, 1(1), 26-29.
Barnett, R., Barta, V. S., & Jhaveri, K. D. (2017). Preserved Renal-Allograft function and the PD-1 pathway inhibitor nivolumab. The New England Journal of Medicine, 376(2), 191-192.
Behshad, R., Garcia-Zuazaga, J., & Bordeaux, J. S. (2011). Systemic treatment of locally advanced nonmetastatic cutaneous squamous cell carcinoma: A review of the literature. The British Journal of Dermatology, 165(6), 1169-1177.
Blum, V., Müller, B., Hofer, S., Pardo, E., Zeidler, K., Diebold, J., … Gautschi, O. (2018). Nivolumab for recurrent cutaneous squamous cell carcinoma: Three cases. European Journal of Dermatology, 28(1), 78-81.
Borradori, L., Sutton, B., Shayesteh, P., & Daniels, G. A. (2016). Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: Preliminary experience in five cases. The British Journal of Dermatology, 175(6), 1382-1386.
Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., … Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine, 366(26), 2455-2465.
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., … Frampton, G. M. (2017). Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine, 9(1), 34.
Chambon, F., Osdoit, S., Bagny, K., Moro, A., Nguyen, J., & Réguerre, Y. (2018). Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatric Blood & Cancer, 65(2), 21-25.
Chang, A. L., Kim, J., Luciano, R., Sullivan-Chang, L., & Colevas, A. D. (2016). A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor. JAMA Dermatology, 152(1), 106-108.
Chen, A., Ali, N., Boasberg, P., & Ho, A. S. (2018). Clinical remission of cutaneous squamous cell carcinoma of the auricle with cetuximab and nivolumab. Journal of Clinical Medicine, 7(1), 1-7.
Clark, R. A., Huang, S. J., Murphy, G. F., Mollet, I. G., Hijnen, D., Muthukuru, M., … Kupper, T. S. (2008). Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. The Journal of Experimental Medicine, 205(10), 2221-2234.
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W. J., Weber, J. S., Ribas, A., … Hamid, O. (2016). Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology, 34(34), 4102-4109.
Degache, E., Crochet, J., Simon, N., Tardieu, M., Trabelsi, S., & Moncourier, M. (2018). Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 32(7), e257-e258.
Deinlein, T., Lax, S. F., Schwarz, T., Giuffrida, R., Schmid-Zalaudek, K., & Zalaudek, I. (2017). Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature. European Journal of Cancer, 83, 99-102.
Euvrard, S., Kanitakis, J., & Claudy, A. (2003). Skin cancers after organ transplantation. The New England Journal of Medicine, 348(17), 1681-1691.
Maubec, E., Helfen, S., Scheer-Senyarich, I., Boubaya, M., Schischmanoff, O., & Alloux, C. (2019). CARSKIN: Pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC). Journal of Clinical Oncology, 35, 15.
Conforti, C., Corneli, P., Harwood, C., & Zalaudek, I. (2019). Evolving role of systemic therapies in non-melanoma skin cancer. Clinical Oncology (Royal College of Radiologists), 31(11), 759-768.
Falchook, G. S., Leidner, R., Stankevich, E., Piening, B., Bifulco, C., & Lowy, I. (2016). Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. Journal for Immunotherapy of Cancer, 4, 70.
Ferrarotto, R. (2017). Efficacy of pembrolizumab in patients with cutaneous squamous cell carcinoma. Journal for Immunotherapy of Cancer, 5, 425.
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Saba, N. F. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 375(19), 1856-1867.
Hauschild, A., Eichstaedt, J., Möbus, L., Kähler, K., Weichenthal, M., Schwarz, T., & Weidinger, S. (2017). Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. European Journal of Cancer, 77, 84-87.
Horn, L., Spigel, D. R., Vokes, E. E., Holgado, E., Ready, N., & Steins, M. (2017). Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). Journal of Clinical Oncology, 35(35), 3924-3933.
Kaplon, H., & Reichert, J. M. (2019). Antibodies to watch in 2019. MAbs, 11(2), 219-238.
Licitra, L., Siu, L., Cohen, E., Zhang, P., Gumuscu, B., Swaby, R., & Harrington, K. (2017). KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC). Annals of Oncology, 28(suppl_11). https://doi.org/10.1093/annonc/mdx711
Lipson, E. J., Bagnasco, S. M., Moore, J., Jr., Jang, S., Patel, M. J., Zachary, A. A., … Drake, C. G. (2016). Tumor regression and allograft rejection after administration of anti-PD-1. The New England Journal of Medicine, 374(9), 896-898.
Lipson, E. J., Forde, P. M., Hammers, H. J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015). Antagonists of PD-1 and PD-L1 in cancer treatment. Seminars in Oncology, 42(4), 587-600.
Markham, A., & Duggan, S. (2018). Cemiplimab: First global approval. Drugs, 78(17), 1841-1846.
Martinez, J. C., Otley, C. C., Okuno, S. H., Foote, R. L., & Kasperbauer, J. L. (2014). Chemotherapy in the management of advanced cutaneous squamous cell carcinoma in organ transplant recipients: Theoretical and practical considerations. Dermatologic Surgery, 30(4 Pt 2), 679-686.
Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., & Lewis, K. D. (2018). PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. The New England Journal of Medicine, 379(4), 341-351.
Miller, D. M., Faulkner-Jones, B. E., Stone, J. R., & Drews, R. E. (2017). Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Reports, 3(5), 412-415.
Palmieri, G., Colombino, M., Cossu, A., Marchetti, A., Botti, G., & Ascierto, P. A. (2017). Genetic instability and increased mutational load: Which diagnostic tool best direct patients with cancer to immunotherapy? Journal of Translational Medicine, 15(1), 17.
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264.
Pembrolizumab in Patients with Locally Advanced or Metastatic Skin Cancer. (2017). Retrieved from https://clinicaltrials.gov/ct2/show/record/NCT02964559
Pickering, C. R., Zhou, J. H., Lee, J. J., Drummond, J. A., Peng, S. A., Saade, R. E., … Frederick, M. J. (2014). Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clinical Cancer Research, 20(24), 6582-6592.
Kudchadkar, R. R., Yushak, M. L., Lawson, D. H., Delman, K. A., Lowe, M. C., Goings, M., … Pollack, B. P. (2018). Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC). Journal of Clinical Oncology, 36, 9543-9543.
Ravulapati, S., Leung, C., Poddar, N., & Tu, Y. (2017). Immunotherapy in squamous cell skin carcinoma: A game changer? The American Journal of Medicine, 130(5), e207-e208.
Ribas, A., & Hu-Lieskovan, S. (2016). What does PD-L1 positive or negative mean? The Journal of Experimental Medicine, 213(13), 2835-2840.
Rogers, H. W., Weinstock, M. A., Feldman, S. R., & Coldiron, B. M. (2012). Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatology, 151(10), 1081-1086.
Salomon, G., Maza, A., Boulinguez, S., Paul, C., Lamant, L., Tournier, E., … Meyer, N. (2018). Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. The British Journal of Dermatology, 178(5), 1199-1203.
Schwab, K. S., Heine, A., Weimann, T., Kristiansen, G., & Brossart, P. (2016). Development of Hemolytic Anemia in a Nivolumab-treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic Leukemia. Case Reports Oncology, 9(2), 373-378.
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., & Eder, J. P. (2016). Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. The Lancet Oncology, 17(7), 956-965.
Sellah, D., Saint-Jean, M., Peuvrel, L., Khammari, A., Quéreux, G., & Dréno, B. (2019). Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature. Journal of the European Academy of Dermatology and Venereology, 33(4), e159-e161.
Stevenson, M. L., Wang, C. Q., Abikhair, M., Roudiani, N., Felsen, D., Krueger, J. G., … Carucci, J. A. (2017). Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatology, 153(4), 299e303.
Stratigos, A., Garbe, C., Lebbe, C., Malvehy, J., del Marmol, V., Pehamberger, H., … European Organization for Research and Treatment of Cancer (EORTC). (2015). Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. European Journal of Cancer, 51(14), 1989-2007.
Tran, D. C., Colevas, A. D., & Chang, A. L. (2017). Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma. JAMA Dermatology, 153(1), 92-94.
Trodello, C., Pepper, J. P., Wong, M., & Wysong, A. (2017). Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: A systematic review. Dermatologic Surgery, 43(1), 40-49.
Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., … Butler, M. O. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. The New England Journal of Medicine, 377(19), 1824-1835.
Winkler, J. K., Schneiderbauer, R., Bender, C., Sedlaczek, O., Fröhling, S., Penzel, R., … Hassel, J. C. (2017). Anti-programmed cell death-1 therapy in nonmelanoma skin cancer. The British Journal of Dermatology, 176(2), 498-502.
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., & Cowey, C. L. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. The New England Journal of Medicine, 377(14), 1345-1356.
Zalaudek, I., Corneli, P., Vernoni, S., Fedele, D., Papa, G., Conforti, C., … Pizzichetta, M. A. (2019). Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in stage III metastatic cutaneous squamous cell carcinoma. Dermatologic Therapy, 8, e13107.